at Nasdaq.com (Dec 4, 2014)
Shares of Medgenics (MDGN +25%) soar after the company says its Infradure Biopump has received an Orphan Drug Designation from the FDA to treat hepatitis D. The designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process. Seeking Alpha contributor Ray Dirks says the designation makes it a prime takeout target.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs